Literature DB >> 12528130

Paraplegia in a patient receiving anti-tumor necrosis factor therapy for rheumatoid arthritis: comment on the article by Mohan et al.

C J van der Laken, W F Lems, R M van Soesbergen, J J van der Sande, B A C Dijkmans.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12528130     DOI： 10.1002/art.10629

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  4 in total

Review 1.  Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety.

Authors:  K L Hyrich; A J Silman; K D Watson; D P M Symmons
Journal:  Ann Rheum Dis       Date:  2004-07-08       Impact factor: 19.103

Review 2.  Use of corticosteroid sparing systemic immunosuppression for treatment of corticosteroid dependent optic neuritis not associated with demyelinating disease.

Authors:  T D Myers; J R Smith; M S Wertheim; R A Egan; W T Shults; J T Rosenbaum
Journal:  Br J Ophthalmol       Date:  2004-05       Impact factor: 4.638

3.  Etanercept-induced myelopathy in a pediatric case of blau syndrome.

Authors:  Fabiola Caracseghi; Jaume Izquierdo-Blasco; Angel Sanchez-Montanez; Susana Melendo-Perez; Manuel Roig-Quilis; Consuelo Modesto
Journal:  Case Rep Rheumatol       Date:  2012-01-15

Review 4.  Chimeric fusion proteins used for therapy: indications, mechanisms, and safety.

Authors:  Brian A Baldo
Journal:  Drug Saf       Date:  2015-05       Impact factor: 5.228
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.